Market Place
Sourcing Support
Biocytogen/Eucure Biopharma to Present Complete Clinical Data from YH003
17 Oct 2023 //
BUSINESSWIRE
Chipscreen bags Chinese rights to Biocytogen`s Keytruda killer
27 Feb 2023 //
FIERCE BIOTECH
FDA approves Biocytogen’s IND application for solid tumour therapy trial
19 Dec 2022 //
CLINICALTRIALSARENA
FDA approves Biocytogen’s IND application for solid tumour therapy trial
19 Dec 2022 //
CLINICALTRIALSARENA
Eucure Announces Partnership with ISU ABXIS for Tri-specific Antibodies
31 Oct 2022 //
BUSINESSWIRE
Syncromune and Eucure enter antibody licence deal
19 Oct 2022 //
PHARMACEUTICAL-TECHNOLOGY
Eucure Biopharma Licenses OX40 Antibody (YH002) and Multiple Active Ingredients
17 Oct 2022 //
BUSINESSWIRE
Biocytogen/Eucure to Present Data from YH003 and YH001 Trials at 2022 ASCO
23 May 2022 //
ASIAONE
Eucure Biopharma Begins Dosing for P I Trial of YH002 + YH001
08 Mar 2022 //
PRNEWSWIRE
Biocytogen/Eucure Biopharma Completes First Patient Dosing for Phase II of YH003
10 Dec 2021 //
PRNEWSWIRE
Eucure`s CTLA-4 & CD40 mAbs Approved for Phase II Clinical Trials by the FDA
06 Jul 2021 //
KOREAHERALD
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.